April 1, 2025 11:00 AM EDT
R&D

Ax­some re­ports Phase 3 de­pres­sion fail for Sunosi

Max Gelman

Senior Editor

Ax­some Ther­a­peu­tics said Tues­day that a Phase 3 tri­al for its nar­colep­sy drug Sunosi failed to meet its pri­ma­ry goal in ma­jor de­pres­sive dis­or­der. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Q&A: John Crow­ley warns biotech is 'dan­ger­ous­ly close' to break­ing, as tar­iff threat, mar­kets bat­ter in­dus­try

Day af­ter mass FDA fir­ings, new com­mis­sion­er ad­dress­es re­main­ing staff, fo­cus­ing on 'MA­HA' vi­sion

Fir­ings sweep across FDA as for­mer lead­ers lament the gut­ting of drug agency

Roche says Ocre­vus failed Phase 3 study; Sanofi li­cens­es au­toim­mune as­set from Nurix

FDA cuts stir buy­er’s re­morse for some bio­phar­ma lead­ers, once ex­cit­ed by Trump

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times